Evotec to Screen for Hits against Active Biotech Immune Disorder and...

Company will use high-throughput and surface plasmon resonance screening with its Lead Discovery Library.

BioInvent and Human Genome Sciences Pool Expertise for mAb Therapeutics Alliance

Partnership will initially focus on HGS targets in the field of inflammation. This represents the latest step in the HGS New Targets Initiative.

Lonza Inks Deal with Odyssey Thera Expanding Drug-Discovery and Safety-Testing Offerings

Lonza will provide Odyssey’s PCA platform and will work with the firm on further product development.

Sigma-Aldrich to Provide Knockout Rats for ADME/Tox

While one model is already available, three more will be introduced later this year.

INC Research to Offer invivodata ePRO Solutions

INC Research signed a deal that allows it to offer invivodata’s electronic patient reported outcomes (ePRO) solutions and services as part of its contract...

Vaxart Raises $12.5M to Progress Oral Vaccine for Avian Flu

Firm’s adjuvant technology targets TLR3, which is active in the gastrointestinal tract.

GSK to Use Gentronix’ GreenScreen HC and BlueScreen HC Genotoxicity Assays

Gentronix entered into a three-year agreement to provide GlaxoSmithKline (GSK) with GreenScreen HC and BlueScreen HC genotoxicity assays. The reporter-based assays have demonstrated the...

Lonza Enters Pluripotent Stem Cell Market through Distribution Arrangement for...

Axiogenesis claims that its Cor.At murine ESC-derived cardiomyocytes represent the first physiologically relevant disease model of cardiomyopathy.

BMS Gives Up $40M in Exchange for Allergan’s Neuropathic Pain Drug

Agreement covers AGN-209323 and backup molecules for all indications except ocular diseases. Milestone fees could reach $373 million.

BMS’ Transplant-Rejection Drug Passes FDA’s Advisory Panel

Despite some concerns over serious adverse events and long-term efficacy, members cited the need for alternatives.